Dr. Horan, Dr. Sauder, Dr. Ramsay, and Dr. Yohn are employees of Bristol Myers Squibb. Dr. Harvey has received consulting fees or travel reimbursement from Alkermes, Boehringer-Ingelheim, Bristol Myers Squibb, Karuna Therapeutics, Merck, Minerva Neuroscience, and Sunovion/DSP; he has received royalties for the Brief Assessment of Cognition in Schizophrenia (owned by WCG); and he is chief scientific officer of i-Function, Inc., and a scientific consultant for EMA Wellness, Inc. Dr. Ramsay holds and is owed restricted stock units at Bristol Myers Squibb. Dr. Keefe has served as a consultant for Biogen, Boehringer-Ingelheim, Bristol Myers Squibb, Gedeon Richter, Neurocrine Pangea, Recognify, Sirtsei, Vandria, and WCG; he has received royalties for the BACS, SCoRS, and VRFCAT; he has received support from Boehringer Ingelheim for attending meetings and/or travel; and he has participated in data safety monitoring boards or advisory boards for Boehringer-Ingelheim, Karuna, Merck, and Neurocrine. Dr. Davis has served as a consultant for Abyrx, Arkana Laboratories, Boehringer Ingelheim, Bristol Myers Squibb, Eikonoklastes Therapeutics, Harm Reduction Therapeutics, LyGenesis, Renerva, University of North Carolina School of Medicine, Division of Nephropathology, and VeraSci. Dr. Paul was an employee of and had a leadership/fiduciary role at Karuna Therapeutics at the time this research was conducted, and he has a leadership/fiduciary role at Sage Therapeutics and Voyager Therapeutics; he holds equity in Eli Lilly, NeuMarker, Rapport Therapeutics, Sage Therapeutics, Seaport Therapeutics, and Voyager Therapeutics. Dr. Brannan was an employee of Karuna Therapeutics at the time this research was conducted and is currently a consultant for Bristol Myers Squibb.